ProCE Banner Activity

FLAURA2: Phase III Trial of First-line Osimertinib ± Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC

Conference Coverage

Primary results from the FLAURA2 trial show osimertinib plus platinum-pemetrexed chemotherapy significantly improves PFS vs osimertinib alone in treatment-naive patients with EGFR-mutated advanced NSCLC.

Released: September 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc